<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cholera: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cholera: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cholera: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason B Harris, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Regina LaRocque, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Firdausi Qadri, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H716941688"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cholera is a life-threatening diarrheal illness caused by cholera toxin-producing strains of <em>Vibrio cholerae</em>. </p><p>Issues related to treatment and prevention of cholera will be reviewed here. Other issues related to cholera are discussed separately. (See  <a class="medical medical_review" href="/d/html/2704.html" rel="external">"Cholera: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2750448512"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3008701245"><span class="h2">Absence of severe malnutrition</span><span class="headingEndMark"> — </span>Fluid management is the cornerstone of cholera treatment [<a href="#rid1">1,2</a>]. Administration of appropriate rehydration therapy reduces the mortality of severe cholera from &gt;10 percent to &lt;0.5 percent [<a href="#rid1">1</a>].</p><p>Antibiotics are an adjunctive therapy for patients with moderate to severe volume depletion. </p><p>Ensuring adequate nutrition is important for all patients; children may also benefit from supplementation of certain micronutrients.</p><p class="headingAnchor" id="H536941403"><span class="h3">Fluid management</span><span class="headingEndMark"> — </span>Fluid management is guided by assessment of volume depletion and ongoing fluid losses. </p><p class="headingAnchor" id="H3582472680"><span class="h4">Assessment of fluid loss</span><span class="headingEndMark"> — </span>Volume status may be determined by assessment of the mental status, eyes, mouth, and skin  (<a class="graphic graphic_table graphicRef68271" href="/d/graphic/68271.html" rel="external">table 1</a>). Based on physical findings, the degree of volume depletion can be categorized by World Health Organization (WHO) criteria as no dehydration (&lt;5 percent of body weight), some dehydration (5 to 10 percent of body weight), or severe dehydration (&gt;10 percent of body weight). </p><p>Cholera cots are useful for estimating stool volume losses  (<a class="graphic graphic_picture graphicRef70839" href="/d/graphic/70839.html" rel="external">picture 1</a>); if these are not available, ongoing losses may be estimated at 10 to 20 mL/kg of body weight for each episode of diarrhea or vomiting. </p><p class="headingAnchor" id="H709222513"><span class="h4">Fluid resuscitation</span><span class="headingEndMark"> — </span>The type and quantity of fluids to administer is determined by the level of volume depletion  (<a class="graphic graphic_table graphicRef68271" href="/d/graphic/68271.html" rel="external">table 1</a>) and an assessment of ongoing fluid losses  (<a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>). </p><p>The most common error in caring for patients with cholera is underestimating the amount of fluid needed to correct volume depletion and replace ongoing losses. Patients with cholera typically present with more severe volume depletion, have more rapid fluid losses (typically 10 to 20 mL/kg/hour), and have proportionally greater stool electrolyte losses than patients with non-cholera gastroenteritis [<a href="#rid3">3,4</a>]. </p><p>Issues related to fluid repletion for adults and children with acute diarrhea are discussed further separately. (See  <a class="medical medical_review" href="/d/html/13954.html" rel="external">"Approach to the adult with acute diarrhea in resource-limited settings", section on 'Rehydration'</a> and  <a class="medical medical_review" href="/d/html/13956.html" rel="external">"Approach to the child with acute diarrhea in resource-limited settings", section on 'Fluid and electrolytes'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>No dehydration (&lt;5 percent) or some dehydration (5 to 10 percent)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach </strong>– Use of oral rehydration solution (ORS):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with no dehydration, ORS should be administered to replace ongoing losses  (<a class="graphic graphic_table graphicRef93208" href="/d/graphic/93208.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with some dehydration, ORS should be administered to correct the fluid deficit  (<a class="graphic graphic_table graphicRef57007" href="/d/graphic/57007.html" rel="external">table 3</a>), then continued for replacement of ongoing losses  (<a class="graphic graphic_table graphicRef93208" href="/d/graphic/93208.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent2">ORS is as effective as and more practical than intravenous fluid repletion in this setting (see  <a class="medical medical_review" href="/d/html/6129.html" rel="external">"Oral rehydration therapy", section on 'Efficacy'</a>). </p><p></p><p class="bulletIndent2">Indications for intravenous hydration include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with profound vomiting (more than three times in one hour) or ongoing stool losses; in such cases, administration of intravenous therapy in conjunction with ORS may be warranted to prevent progression to severe dehydration.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who are unable to drink because of vomiting or altered mental status. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ORS formulation</strong> – Types of ORS are summarized in the table  (<a class="graphic graphic_table graphicRef93208" href="/d/graphic/93208.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent2">The WHO recommended use of a reduced osmolar glucose-based ORS in 2002; other formulations include a rice-based formulation (using rice powder rather than glucose) or home-made ORS (using sugar, salt, and clean water). </p><p></p><p class="bulletIndent2">Use of the WHO 2002 formulation has been shown to reduce stool output, vomiting, and the need for supplemental intravenous fluids [<a href="#rid5">5</a>]. Among patients with cholera, subclinical hyponatremia is common with this ORS formulation, but rates of symptomatic hyponatremia do not appear to be significantly increased [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent2">Rice-based ORS has been demonstrated to reduce the duration of diarrhea and stool losses in severe cholera; however, it is more complex to prepare [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent2">Additional details related to ORS are discussed further separately. (See  <a class="medical medical_review" href="/d/html/6129.html" rel="external">"Oral rehydration therapy", section on 'Commercial and standard oral rehydration solutions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe dehydration (&gt;10 percent)</strong> – For patients with severe dehydration, intravenous fluids should be administered urgently  (<a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid quantity</strong> – For patients ≥1 year of age without severe malnutrition, a fluid volume of 100 mL/kg should be administered over three hours; an initial volume of 30 mL/kg should be given over the first 30 minutes. </p><p></p><p class="bulletIndent2">For patients &lt;1 year of age without severe malnutrition, a fluid volume of 100 mL/kg should be administered over six hours; an initial volume of 30 mL/kg should be given over the first 30 minutes. </p><p></p><p class="bulletIndent2">In the first 24 hours of treatment, patients with severe cholera typically require an average of 200 mL/kg of isotonic oral or intravenous fluids and may require more than 350 mL/kg [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent2">Issues related to fluid management for children with severe dehydration in the setting of severe malnutrition are discussed separately. (See  <a class="medical medical_review" href="/d/html/5901.html" rel="external">"Management of complicated severe acute malnutrition in children in resource-limited settings"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid formulation</strong> – Intravenous Ringer's lactate is the best commercially available intravenous solution for rehydration of patients with severe dehydration due to cholera, since it includes potassium and <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> — both of which are lost in cholera stools  (<a class="graphic graphic_table graphicRef93208" href="/d/graphic/93208.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent2">Locally prepared solutions, such as "Dhaka solution" (which contains glucose and more potassium than Ringer's lactate), are available in some cholera-endemic regions; such preparations may mitigate potential complications including hypokalemia, hypoglycemia, and metabolic acidosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Access to rehydration therapy</strong> – Access to appropriate rehydration therapy is an important obstacle, particularly during cholera epidemics. For this reason, a community-based response and strategic use of decentralized treatment centers (ie, oral rehydration points) to improve access to treatment are crucial to successful management of cholera outbreaks [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H3079233854"><span class="h4">Continued monitoring</span><span class="headingEndMark"> — </span>Volume status should be assessed via physical exam on an ongoing basis  (<a class="graphic graphic_table graphicRef68271" href="/d/graphic/68271.html" rel="external">table 1</a>), and the rate of fluid repletion should be adjusted if needed. </p><p>Once the fluid volume to replace the estimated initial deficit has been administered, patients should be managed based on the estimated degree of residual volume depletion from ongoing losses. In general, children ≤2 years of age should receive 50 to 100 mL of fluid for each episode of diarrhea or vomiting; children &gt;2 years of age should receive 100 to 200 mL of fluid for each episode. For adults, stool output may be estimated at 10 to 20 mL/kg. Stool output may also be measured by collecting stool using a cholera cot.</p><p>In patients treated with proper rehydration, diarrhea is most severe during the first two days and resolves after four to six days [<a href="#rid9">9-11</a>]. </p><p class="headingAnchor" id="H768821309"><span class="h3">Antibiotic therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use and rationale </strong>–<strong> </strong>Antibiotics are warranted for patients with cholera and moderate to severe dehydration. In such patients, antibiotic therapy can shorten the duration of diarrhea to 48 hours, reduce the volume of stool losses by up to 50 percent, and shorten the duration of stool shedding of <em>V. cholerae </em>from 5 days to 1 or 2 days [<a href="#rid12">12,13</a>]. However, antibiotic therapy has not been demonstrated to control cholera outbreaks [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – Antibiotics may be administered as soon as the patient is able to take oral medications. Antibiotic options include macrolides, fluoroquinolones, and tetracyclines  (<a class="graphic graphic_table graphicRef71548" href="/d/graphic/71548.html" rel="external">table 4</a>); selection should be based on availability and local resistance patterns.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug efficacy and drug resistance</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tetracyclines</strong> – Tetracyclines are the antibiotic class for which there is greatest clinical experience for treatment of cholera infection [<a href="#rid12">12</a>]. In a randomized trial including 246 patients in Bangladesh with severe dehydration and tetracycline-susceptible <em>V. cholerae</em>, the efficacy of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (single 300 mg dose) and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> (500 mg every 6 hours for 2 days) were comparable with respect to stool output, duration of diarrhea, vomiting, and requirement for ORS [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent2">However, resistance to <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> and <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> is common [<a href="#rid16">16-18</a>]; empiric use of these agents should be limited to settings where ongoing surveillance indicates that most strains are susceptible to this antibiotic class. In regions where tetracycline resistance is common, fluoroquinolones and macrolides are alternative agents; however, fluoroquinolone resistance has also become common in endemic areas [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluoroquinolones</strong> – Fluroquinolone efficacy is comparable to or greater than <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> efficacy for treatment of cholera infection [<a href="#rid20">20-22</a>]. In one randomized trial including 260 adults with <em>V. cholerae</em> O1 or O139 infection in Bangladesh, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (1000 mg single dose) was effective against both strains, and superior to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (300 mg single dose) in eradicating organisms from stool [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent2">However, decreased fluoroquinolone susceptibility has emerged with increasing use of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> to treat cholera [<a href="#rid23">23,24</a>]. For treatment of patients with cholera due to isolates with decreased fluoroquinolone susceptibility (identified by resistance to nalidixic acid), administration of a three-day regimen has been associated with higher rates of clinical and bacteriologic response than a single-dose regimen [<a href="#rid25">25</a>]. Such nalidixic acid resistant strains remain common among the current pandemic circulating lineage of <em>V. cholerae</em> [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Macrolides</strong> – Macrolides are also effective for treatment of cholera [<a href="#rid23">23,24,28-30</a>]. In a trial including 128 children with cholera in India, the clinical and bacteriologic efficacy of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (20 mg/kg single dose) and <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> (12.5 mg/kg every six hours for three days) were similar; azithromycin was associated with less vomiting [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent2">Some trials have demonstrated greater efficacy with macrolides compared with fluoroquinolones, perhaps because of decreased susceptibility of <em>V. cholerae</em> strains to fluoroquinolones. As an example, in a randomized trial including 195 adults with severe cholera in Bangladesh, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (1 gram single dose) was superior to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> (1 gram single dose) with regards to clinical efficacy (73 versus 27 percent ceased to have watery stool at 48 hours) and bacteriologic efficacy (78 versus 10 percent eradication <em>of V. cholerae</em> from stools at 48 hours) [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent2">Rarely, <em>V. cholerae</em> O1 strains with macrolide resistance have been reported [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent2">Most <em>V. cholerae</em> O139 strains and many O1 El Tor strains are resistant to <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> and furazolidone [<a href="#rid18">18</a>]. </p><p></p><p class="headingAnchor" id="H1498616155"><span class="h3">Nutrition, vitamins, and minerals</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – Eating should resume as soon as possible after the initial fluid deficit is corrected, and breastfeeding of infants should be encouraged in conjunction with oral rehydration solution. Sufficient feeding should be encouraged to prevent malnutrition and facilitate recovery of normal gastrointestinal function [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">Children with severe malnutrition require an individualized approach to nutritional repletion; this is discussed further separately. (See  <a class="medical medical_review" href="/d/html/5901.html" rel="external">"Management of complicated severe acute malnutrition in children in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamins and minerals</strong> – Among children with acute diarrhea, zinc and vitamin A supplementation are also important interventions. Zinc supplementation reduces the duration and volume of stool in children with cholera [<a href="#rid32">32</a>]. This is discussed separately. (See  <a class="medical medical_review" href="/d/html/13956.html" rel="external">"Approach to the child with acute diarrhea in resource-limited settings", section on 'Vitamins and minerals'</a>.)</p><p></p><p class="headingAnchor" id="H3902160896"><span class="h2">Presence of severe malnutrition</span><span class="headingEndMark"> — </span>Children with acute diarrhea and severe malnutrition require an individualized approach to rehydration and nutritional repletion. These issues are discussed further separately. (See  <a class="medical medical_review" href="/d/html/5901.html" rel="external">"Management of complicated severe acute malnutrition in children in resource-limited settings"</a> and  <a class="medical medical_review" href="/d/html/5878.html" rel="external">"Persistent diarrhea in children in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H2210905441"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>Mortality in untreated patients may reach 50 to 70 percent in severe cholera [<a href="#rid16">16,33</a>]. Administration of appropriate rehydration therapy can reduce the mortality of severe cholera to &lt;0.5 percent [<a href="#rid34">34</a>]. In endemic areas, the risk of mortality risk is highest in children (10 times greater than in adults) [<a href="#rid35">35,36</a>]. </p><p>Early studies suggested a high risk of fetal death associated with cholera during pregnancy (up to 50 percent during the third trimester); subsequent studies have reported a risk of approximately 8 percent [<a href="#rid37">37,38</a>].</p><p class="headingAnchor" id="H827095468"><span class="h1">PREVENTING TRANSMISSION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In endemic areas</strong> – Cornerstones of cholera prevention include access to safely managed water and appropriate sanitation. In resource-limited settings, these can be difficult to achieve; worldwide, more than 1 in 4 people lack access to safely managed water and 2 out of 5 lack access to safely managed home sanitation [<a href="#rid39">39,40</a>]. Universal safe water and sanitation are urgently needed in many areas of the world. </p><p></p><p class="bulletIndent1">Smaller-scale interventions to reduce cholera risk include point-of-use water treatment, safe storage of water systems using simple vessels with lids and taps, provision of sanitation facilities (including latrines and flush toilets), and behavior change campaigns targeted at increasing handwashing [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">Breastfeeding of young infants is protective against cholera and other enteric infections (see  <a class="medical medical_review" href="/d/html/5013.html" rel="external">"Infant benefits of breastfeeding", section on 'Prevention of illnesses while breastfeeding'</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For travelers</strong> – Travelers to regions where cholera is endemic should follow the general precautions for the prevention of travelers' diarrhea [<a href="#rid41">41</a>]. This includes avoidance of tap water, food from street vendors, raw or undercooked seafood, and raw vegetables [<a href="#rid42">42</a>]. Water can be treated with chlorine or iodine, by filtration, or by boiling [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/3898.html" rel="external">"Travel advice", section on 'Food and water'</a>.)</p><p></p><p class="headingAnchor" id="H3006845242"><span class="h1">VACCINATION</span></p><p class="headingAnchor" id="H60687214"><span class="h2">Human immunity</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunity following natural infection</strong> – <em>V. cholerae</em> O1 infection results in immunity against reinfection and disease [<a href="#rid44">44,45</a>]<em>.</em> In one cohort including more than 4600 patients with cholera detected in Bangladesh between 1991 and 2000, natural infection resulted in 65 percent protection (95% CI, 37-81) relative to age-matched controls over three-year follow-up [<a href="#rid45">45</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibody response</strong> – The mechanisms mediating mucosal immunity against <em>V. cholerae</em> are not well understood. The major targets of the human antibody response to <em>V. cholerae</em> O1 consist of the O-specific polysaccharide and cholera toxin [<a href="#rid46">46</a>]. Antibodies that target the O1-specific polysaccharide are likely critical for protection [<a href="#rid47">47</a>]; however, antibodies to cholera toxin appear to play a limited role in protection, since immunization with inactivated cholera toxin provides only short-term immunity [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correlates of protection</strong> – There are no well-established correlates of protection for cholera. Correlates of protection are immunologic markers (following infection or vaccination) associated with a decreased risk of subsequent infection; they can be used to evaluate early vaccine candidates or as proxy measurements of vaccine efficacy in clinical trials. </p><p></p><p class="bulletIndent1">Vibriocidal antibody titers are imperfect correlates of protection for cholera but have been used as a proxy for efficacy for cholera vaccine-induced protection [<a href="#rid49">49,50</a>]. A combination of several immunologic markers may serve as a better correlation of protection than the vibriocidal antibody [<a href="#rid51">51</a>]; however, thus far such a correlate has not been used to support cholera vaccine approval.</p><p></p><p class="headingAnchor" id="H1591502722"><span class="h2">Vaccine formulations and efficacy</span><span class="headingEndMark"> — </span>The first parenteral whole-cell cholera vaccines were developed shortly after <em>V. cholerae</em> was isolated by Robert Koch in 1883 [<a href="#rid52">52</a>]. The efficacy of these vaccines was approximately 80 percent [<a href="#rid53">53</a>], but they were associated with significant reactogenicity. They fell from favor after clinical trials in Bangladesh in the 1960s demonstrated only short-lived protection [<a href="#rid54">54</a>]. </p><p class="headingAnchor" id="H1345825258"><span class="h3">Available vaccines</span><span class="headingEndMark"> — </span>Available cholera vaccines are summarized in the table. </p><p class="headingAnchor" id="H2819208313"><span class="h4">Inactivated oral cholera vaccines</span><span class="headingEndMark"> — </span>Inactivated oral cholera vaccines include bivalent killed whole-cell vaccines (WC) and a killed whole cell vaccine with a recombinant B subunit (<a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a>). </p><p>In a meta-analysis  (<a class="graphic graphic_table graphicRef143626" href="/d/graphic/143626.html" rel="external">table 5</a>) including seven clinical trials and six observational studies evaluating these vaccines, the average effectiveness of a two-dose series was 76 percent; however, among children &lt;5 years of age the average efficacy was 30 percent [<a href="#rid55">55</a>]. </p><p class="headingAnchor" id="H2799942430"><span class="h5">Bivalent WC</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulation</strong> – Bivalent WC vaccines contain killed whole cells of several biotypes and serotypes of <em>V. cholerae</em> O1 and <em>V. cholerae</em> O139 without supplemental cholera toxin B subunit. They are formulated with heat- and formalin-inactivated <em>V. cholerae</em> strains, including a combination of the O1 Inaba and O1 Ogawa serotypes derived from the Classical and El Tor biotypes, and the now-rare <em>V. cholerae</em> O139 serogroup. There are four available formulations  (<a class="graphic graphic_table graphicRef143626" href="/d/graphic/143626.html" rel="external">table 5</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use</strong> – Two bivalent WC formulations are included in the global stockpile; a third is approved and licensed in Bangladesh, and a fourth is approved and licensed in Vietnam  (<a class="graphic graphic_table graphicRef143626" href="/d/graphic/143626.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Two-dose series</strong> – In a meta-analysis including seven clinical trials and six observational studies evaluating the <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> and bivalent WC, the average effectiveness of a two-dose series was 76 percent (95% CI, 62-85); however, among children &lt;5 years of age the average efficacy was 30 percent (95% CI, 15-42) [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent2">In randomized trials, the efficacy of bivalent WC has ranged from 53 to 67 percent, with protection persisting for five years among adults but shorter durability among children ≤5 years of age (42 percent at five years) [<a href="#rid56">56-59</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>A single dose confers some benefit</strong> – For situations in which the two-dose series cannot be given, a single dose provides some protection for older children and adults. In a randomized trial evaluating Shanchol (single dose), adjusted six-month efficacy was 40 and 63 percent for all and severely dehydrating cholera, respectively, and protection was sustained over at least two years [<a href="#rid58">58,60</a>]. However, there was no evidence of protection in children under five years of age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Herd immunity</strong> – Use of bivalent WC vaccine confers herd protection. In a cluster-randomized trial in India, more than 66,000 individuals were randomly assigned to receive cholera vaccine or placebo; among placebo recipients, the risk of cholera was inversely related to neighborhood-level vaccine coverage [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Control of outbreak and epidemic cholera</strong> – Vaccination with bivalent WC vaccine shortly after the onset of a cholera outbreak provides some protection within the first several months following administration. In a case-control study following a cholera outbreak in Guinea, two doses of Shanchol were associated with an adjusted vaccine effectiveness of 87 percent [<a href="#rid62">62</a>]. In a case-control study in Haiti, a two-dose series was associated with effectiveness of 76 percent over a four-year period; however, for those who received a single dose, effectiveness declined from 79 percent in the first year to no detectable effectiveness by two years after vaccination [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H2354903038"><span class="h5">WC-rBS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulation</strong> – <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> (Dukoral) contains killed whole cells of several biotypes and serotypes of <em>V. cholerae</em> O1 in addition to recombinant cholera toxin B subunit (the nonenzymatically active portion of cholera toxin which binds to the cell surface receptor). This vaccine is not effective against <em>V. cholerae</em> O139. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use</strong> – <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> is used primarily for travelers from Canada or Europe to areas of active cholera transmission. It is recommended for individuals ≥2 years of age  (<a class="graphic graphic_table graphicRef143626" href="/d/graphic/143626.html" rel="external">table 5</a>). Revaccination is recommended for ongoing exposure. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1">Production of <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> is more expensive than production of bivalent WC vaccines (which do not include the recombinant cholera toxin B subunit) (see <a class="local">'Bivalent WC'</a> above). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Two-dose series</strong> – In a meta-analysis including seven clinical trials and six observational studies evaluating the <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> and bivalent WC, the average effectiveness of a two-dose series was 76 percent (95% CI, 62- 85); however, among children &lt;5 years of age the average efficacy was 30 percent (95% CI, 15-42) [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent2">The precursor to <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> was evaluated in a randomized trial in Bangladesh including more than 62,000 participants randomly assigned to receive B subunit-killed whole cell vaccine (BS-WC), killed whole cell-only vaccine (WC), or placebo (inactivated non-toxigen<em>ic Escherichia coli</em> vaccine) [<a href="#rid64">64</a>]. Over a five-year follow-up period, the WC and BS-WC vaccines were associated with protective efficacy of 47 percent and 49 percent, respectively, compared with placebo [<a href="#rid64">64</a>]. Protection waned more rapidly among children &lt;5 years of age who were not protected after two years of follow-up [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Herd immunity</strong> – Use of <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> confers herd immunity; among unvaccinated individuals in areas of Bangladesh where local vaccine coverage exceeded 50 percent, a fivefold reduction in the risk of cholera was observed compared with unvaccinated individuals in lower vaccine coverage areas (7 versus 1.47 cases per 1000) [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Outbreak control</strong> – The efficacy of <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> has also been evaluated in outbreak settings in Mozambique and Zanzibar [<a href="#rid67">67,68</a>]. In both studies, oral cholera vaccination was undertaken prior to the outbreak, and in both studies, receipt of one or more doses of vaccine was associated with 78 percent protection. Vaccination was equally effective in children ≤5 years and in older individuals [<a href="#rid67">67</a>]. Protection declined rapidly among young children after six months but remained as high as 60 percent in older recipients for two to three years. </p><p></p><p class="headingAnchor" id="H3342332311"><span class="h4">Live attenuated oral cholera vaccine</span></p><p class="headingAnchor" id="H284633088"><span class="h5">CVD 103-HgR</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Formulation</strong> – <a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">CVD 103-HgR</a> (Vaxchora) was derived from a Classical O1 Inaba strain by deletion of the active cholera toxin A subunit. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use</strong> – Issues related to use of <a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">CVD 103-HgR</a> are discussed below. (See <a class="local">'For travelers to high-risk areas'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In a clinical trial including 197 healthy adult volunteers randomly assigned to receive an oral dose of <a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">CVD 103-HgR</a> vaccine or placebo, followed by oral challenge with a <em>V. cholerae O1</em> strain (10 days after vaccine), diarrhea occurred less frequently among vaccine recipients (5.7 versus 59.1 percent; vaccine efficacy 90 percent) [<a href="#rid69">69</a>]. The vaccine was well tolerated without increased rates of diarrhea, other gastrointestinal complaints, or fever. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">CVD 103-HgR</a> was approved for children based on immunogenicity bridging studies; these suggest a similar safety and immunogenicity profile in children [<a href="#rid70">70-73</a>].</p><p></p><p class="bulletIndent1">Few studies of <a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">CVD 103-HgR</a> have been conducted in areas in which cholera is endemic. CVD 103-HgR was evaluated in the 1990s in Indonesia among more than 67,000 individuals age 2 to 41 years of age randomly assigned to receive vaccine or placebo [<a href="#rid74">74</a>]. At four-year follow-up, the efficacy was 14 percent; however, a lower-than-expected incidence of infection was observed [<a href="#rid75">75</a>]. </p><p></p><p class="headingAnchor" id="H562306807"><span class="h3">Vaccines in development</span><span class="headingEndMark"> — </span>Vaccines in development include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hillchol </strong>–<strong> </strong>Hillchol is an inactivated whole-cell vaccine consisting of a formaldehyde-inactivated recombinant <em>V. cholerae </em>strain engineered to expresses the Inaba and Ogawa antigens. Use of a single formaldehyde-inactivated strain is expected to simplify manufacturing and production. Phase I/II studies were reported in 2021 [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholera conjugate vaccine</strong> – Cholera conjugate vaccine consists of the<strong> </strong><em>V. cholerae</em> O1-Inaba specific polysaccharide linked to a recombinant tetanus toxoid heavy chain fragment-carrier protein; this approach may overcome the limited immunogenicity of current vaccines in young children. Scalable production was described in 2021 [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PanChol </strong>– PanChol is a live attenuated vaccine engineered from a 2010 <em>V. cholerae</em> O1 isolate from Haiti; in an animal model, it induced protection within days of vaccination [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H226348592"><span class="h2">Use of vaccines for cholera control</span><span class="headingEndMark"> — </span>Cholera occurs primarily in settings where there is inadequate access to clean water and sanitation; this includes endemic infection (which typically occurs among young children) as well as outbreak or epidemic settings (which often occur in the setting of natural or humanitarian disasters, among adults as well as children). (See  <a class="medical medical_review" href="/d/html/2704.html" rel="external">"Cholera: Epidemiology, clinical features, and diagnosis", section on 'Epidemiology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available vaccines</strong> – Two bivalent WC vaccines, Shanchol and Euvichol-Plus, are used in outbreaks and cholera-endemic countries [<a href="#rid1">1</a>]. Production of Shanchol ceased in 2023. Euvichol has been replaced with Euvichol-Plus, which is packed in plastic containers to facilitate administration by squirting vaccine directly into the mouth. (See <a class="local">'Bivalent WC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of endemic cholera</strong> – Expanding vaccine use for control of endemic cholera is a core component of the World Health Organization (WHO) effort to reduce the global mortality due to cholera by 90 percent between 2017 and 2030 [<a href="#rid79">79</a>]. However, ongoing shortages in the global supply of oral cholera vaccines have limited access to vaccines for this purpose [<a href="#rid80">80</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of outbreak and epidemic cholera</strong> – Forms of vaccination campaigns for outbreak or epidemic control include preventive and reactive: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preventive campaigns</strong> – The goal of a preventive vaccination campaign is to avert a cholera outbreak in a high-risk setting. As an example, a vaccination campaign conducted among Rohingya refugees and the surrounding Cox's Bazar district in Bangladesh effectively averted cholera [<a href="#rid81">81,82</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reactive campaigns</strong> – The goal of a reactive campaign is to limit spread in the context of an ongoing outbreak or epidemic. After introduction of cholera in Haiti in 2010, a reactive vaccination campaign was credited with reducing cholera transmission in Haiti to the point where it was considered eradicated; no cases of cholera occurred between 2019 and early 2022 [<a href="#rid83">83</a>]. </p><p></p><p class="bulletIndent2">Cholera reemerged in Haiti in fall 2022. Based on molecular genomic evidence, reemergence was caused by a direct descendant of the same <em>V. cholerae</em> strain that was introduced in 2010 [<a href="#rid84">84</a>], suggesting that the pathogen may be sustained for prolonged periods by in environmental reservoirs or via transmission episodes which evade detection. </p><p></p><p class="bulletIndent1">Vaccination following onset of an epidemic is effective in reducing the risk of cholera [<a href="#rid62">62</a>]. A single dose of bivalent WC provides some protection and can be used in the setting of a vaccine shortage or if a second dose is not feasible or during a vaccine shortage [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">Countries can apply to the global <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.gtfcc.org%2F&amp;token=JQnhSnq2A20YrM7%2FK7tG%2B4%2FHCMz37uJMZztRZ%2F2ID7I%3D&amp;TOPIC_ID=141337" target="_blank">stockpile</a> for preventive or reactive vaccine campaigns; however, demand still outstrips supply.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine availability</strong> – Vaccine shortages are a limiting factor in cholera control efforts; vaccine production must be increased, including manufacturing in endemic countries [<a href="#rid86">86</a>]. </p><p></p><p class="bulletIndent1">A global cholera vaccine stockpile of bivalent WC was started in 2013; use of this vaccine supply is intended for cholera control in outbreaks, humanitarian crises, and settings with endemic cholera. The stockpile is funded by Gavi, the Vaccine Alliance; emergency deployment from the stockpile is coordinated by an International Coordinating Group (ICG) with WHO serving as the secretariat. Between 2013 and 2017, nearly 17 million vaccine doses were shipped to 18 countries [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1">In 2022, Gavi and the ICG approved production of more than 36 million cholera vaccine doses for preventive and reactive cholera vaccine campaigns; however, only 25.5 million vaccine doses were produced [<a href="#rid87">87</a>]. As a result, in October 2022, the ICG decided to limit all approved reactive oral cholera vaccine campaigns to a single dose, while other pending vaccination campaigns were halted due to an insufficient vaccine supply [<a href="#rid88">88</a>]. </p><p></p><p class="headingAnchor" id="H548735252"><span class="h2">For travelers to high-risk areas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – The United States Centers for Disease Control and Prevention (CDC) recommends vaccination for prevention of cholera in patients age 2 to 64 years of age traveling to an area of active cholera transmission who are at immediate risk of epidemic cholera [<a href="#rid70">70</a>]. An area of active cholera transmission is defined as a region with endemic or epidemic cholera caused by toxigenic <em>V. cholerae</em> O1 and includes areas with cholera activity within the last year that are prone to recurrence of cholera epidemics; it does not include areas where only rare imported or sporadic cases have been reported. </p><p></p><p class="bulletIndent1">Most people do not travel to areas of active cholera transmission, and most travelers are at extremely low risk for cholera infection. Groups that most warrant vaccination include aid, refugee, and health care workers in endemic and epidemic areas in proximity to displaced populations, especially in crowded camps and urban areas with unsanitary conditions. (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States</strong> – In the United States, a <a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">live attenuated cholera vaccine</a> CVD 103-HgR (Vaxchora) that prevents cholera caused by serotype O1 is available for travelers age 2 to 64 years of age who are at high risk of exposure  (<a class="graphic graphic_table graphicRef143626" href="/d/graphic/143626.html" rel="external">table 5</a>) [<a href="#rid70">70</a>]. In 2016, the vaccine was approved by the US Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices (ACIP) for adults age 18 to 64; in 2022, the vaccine was further approved by the FDA and recommended by the ACIP to include children and adolescents age 2 to 17 years of age [<a href="#rid70">70</a>]. (See <a class="local">'CVD 103-HgR'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Canada and Europe</strong> – In Canada and European countries, <a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a> (Dukoral) is available for prevention of cholera caused by serotype O1 in travelers. (See <a class="local">'WC-rBS'</a> above.)</p><p></p><p class="headingAnchor" id="H1422373019"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109942.html" rel="external">"Society guideline links: Acute diarrhea in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H753945936"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Cholera is a life-threatening diarrheal illness caused by cholera toxin-producing strains of <em>Vibrio cholerae</em>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management in absence of severe malnutrition</strong> (See <a class="local">'Absence of severe malnutrition'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluid management</strong> – Fluid management is the cornerstone of cholera treatment  (<a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>). The type and quantity of fluids to administer is determined by the level of volume depletion  (<a class="graphic graphic_table graphicRef68271" href="/d/graphic/68271.html" rel="external">table 1</a>) and assessment of ongoing losses. (See <a class="local">'Fluid management'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with no dehydration, oral rehydration solution (ORS) should be administered to replace ongoing losses  (<a class="graphic graphic_table graphicRef93208" href="/d/graphic/93208.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with some dehydration, ORS should be administered to correct the fluid deficit  (<a class="graphic graphic_table graphicRef93208" href="/d/graphic/93208.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef57007" href="/d/graphic/57007.html" rel="external">table 3</a>), then continued for replacement of ongoing losses  (<a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with severe dehydration, intravenous fluids should be administered urgently  (<a class="graphic graphic_algorithm graphicRef143632" href="/d/graphic/143632.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of antibiotic therapy</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with cholera and moderate to severe dehydration (≥5 percent), we recommend antibiotic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Individuals with &lt;5 percent dehydration do not require antibiotic therapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antibiotics may be administered as soon as the patient is able to take oral medications. Antibiotic options include macrolides, fluoroquinolones, and tetracyclines  (<a class="graphic graphic_table graphicRef71548" href="/d/graphic/71548.html" rel="external">table 4</a>); selection should be based on availability and local resistance patterns. (See <a class="local">'Antibiotic therapy'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nutrition, vitamins, and minerals</strong> – Sufficient feeding should be encouraged. Among children with acute diarrhea, zinc and vitamin A supplementation are also important interventions; this is discussed separately. (See  <a class="medical medical_review" href="/d/html/13956.html" rel="external">"Approach to the child with acute diarrhea in resource-limited settings", section on 'Vitamins and minerals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management in presence of severe malnutrition</strong> – Management of children with acute diarrhea and severe malnutrition is discussed further separately. (See <a class="external" href="%2Fcontents%2Fmanagement-of-complicated-severe-acute-malnutrition-in-children-in-resource-limited-settings%3FsectionName%3DDehydration%26search%3Ddiarrhea%2Bchildren%26topicRef%3D13956%26anchor%3DH9%26source%3Dsee_link%23H9&amp;data=05|01|Ellie.Baron%40wolterskluwer.com|903bfe79aaf5456bfcf108dbe6dbea0b|8ac76c91e7f141ffa89c3553b2da2c17|0|0|638357604434281363|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D|3000|||&amp;sdata=QmvLfY3u%2FM6MjwyuB55MiQqzeVmt4KYY0WN7Zr88Y28%3D&amp;reserved=0" target="_blank">"Management of complicated severe acute malnutrition in children in resource-limited settings", section on 'Dehydration'</a> and <a class="external" href="%2Fcontents%2Fpersistent-diarrhea-in-children-in-resource-limited-settings%3FsectionName%3DRehydration%26search%3Ddiarrhea%2Bchildren%26topicRef%3D13956%26anchor%3DH14%26source%3Dsee_link%23H14&amp;data=05|01|Ellie.Baron%40wolterskluwer.com|903bfe79aaf5456bfcf108dbe6dbea0b|8ac76c91e7f141ffa89c3553b2da2c17|0|0|638357604434281363|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D|3000|||&amp;sdata=te8WwTUKxMAAXRq9qeJ1Nj9Mr3zRsdEYEQ9zf8xjXAA%3D&amp;reserved=0" target="_blank">"Persistent diarrhea in children in resource-limited settings", section on 'Rehydration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preventing transmission</strong> – Cornerstones of cholera control include access to safely managed water and appropriate sanitation. (See <a class="local">'Preventing transmission'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccination </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Available vaccines</strong> – Available vaccines are summarized in the table  (<a class="graphic graphic_table graphicRef143626" href="/d/graphic/143626.html" rel="external">table 5</a>). They include inactivated (Bivalent killed whole cell-only vaccine [WC], killed whole cell vaccine with a recombinant B subunit [<a class="drug drug_general" data-topicid="9489" href="/d/drug information/9489.html" rel="external">WC-rBS</a>]) and live attenuated (<a class="drug drug_general" data-topicid="108665" href="/d/drug information/108665.html" rel="external">CVD 103-HgR</a>) oral formulations. (See <a class="local">'Available vaccines'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cholera control</strong> – In endemic areas, two bivalent WC vaccines are used for control of endemic and outbreak/epidemic cholera. Vaccine shortages are a limiting factor in cholera control efforts. Decisions regarding vaccine implementation should be guided by local public health officials, based in part on vaccine availability. (See <a class="local">'Use of vaccines for cholera control'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kanungo S, Azman AS, Ramamurthy T, et al. Cholera. Lancet 2022; 399:1429.</a></li><li class="breakAll">World Health Organization. The treatment of diarrhoea, a manual for physicians and other senior health workers. 4th revision. WHO/FCH/CAH/05.1. Geneva: World Health Organization, 2005. https://apps.who.int/iris/handle/10665/43209 (Accessed on December 11, 2023).</li><li><a class="nounderline abstract_t">Mahalanabis D, Wallace CK, Kallen RJ, et al. Water and electrolyte losses due to cholera in infants and small children: a recovery balance study. Pediatrics 1970; 45:374.</a></li><li><a class="nounderline abstract_t">Molla AM, Rahman M, Sarker SA, et al. Stool electrolyte content and purging rates in diarrhea caused by rotavirus, enterotoxigenic E. coli, and V. cholerae in children. J Pediatr 1981; 98:835.</a></li><li><a class="nounderline abstract_t">Hahn S, Kim Y, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review. BMJ 2001; 323:81.</a></li><li><a class="nounderline abstract_t">Alam NH, Yunus M, Faruque AS, et al. Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution. JAMA 2006; 296:567.</a></li><li><a class="nounderline abstract_t">Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med 2000; 342:308.</a></li><li><a class="nounderline abstract_t">Ivers LC, Farmer P, Almazor CP, Léandre F. Five complementary interventions to slow cholera: Haiti. Lancet 2010; 376:2048.</a></li><li><a class="nounderline abstract_t">Carpenter CC, Barua D, Wallace CK, et al. Clinical studies in Asiatic cholera. IV. Antibiotic therapy in cholera. Bull Johns Hopkins Hosp 1966; 118:216.</a></li><li><a class="nounderline abstract_t">Hirschhorn N, Kinzie JL, Sachar DB, et al. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N Engl J Med 1968; 279:176.</a></li><li><a class="nounderline abstract_t">Pierce NF, Banwell JG, Mitra RC, et al. Controlled comparison of tetracycline and furazolidone in cholera. Br Med J 1968; 3:277.</a></li><li><a class="nounderline abstract_t">Leibovici-Weissman Y, Neuberger A, Bitterman R, et al. Antimicrobial drugs for treating cholera. Cochrane Database Syst Rev 2014; :CD008625.</a></li><li><a class="nounderline abstract_t">Weil AA, Begum Y, Chowdhury F, et al. Bacterial shedding in household contacts of cholera patients in Dhaka, Bangladesh. Am J Trop Med Hyg 2014; 91:738.</a></li><li><a class="nounderline abstract_t">Nelson EJ, Nelson DS, Salam MA, Sack DA. Antibiotics for both moderate and severe cholera. N Engl J Med 2011; 364:5.</a></li><li><a class="nounderline abstract_t">Alam AN, Alam NH, Ahmed T, Sack DA. Randomised double blind trial of single dose doxycycline for treating cholera in adults. BMJ 1990; 300:1619.</a></li><li><a class="nounderline abstract_t">Siddique AK, Salam A, Islam MS, et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet 1995; 345:359.</a></li><li><a class="nounderline abstract_t">Siddique AK, Zaman K, Majumder Y, et al. Simultaneous outbreaks of contrasting drug resistant classic and El Tor Vibrio cholerae O1 in Bangladesh. Lancet 1989; 2:396.</a></li><li><a class="nounderline abstract_t">Kitaoka M, Miyata ST, Unterweger D, Pukatzki S. Antibiotic resistance mechanisms of Vibrio cholerae. J Med Microbiol 2011; 60:397.</a></li><li><a class="nounderline abstract_t">Islam MS, Midzi SM, Charimari L, et al. Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA 2009; 302:2321.</a></li><li><a class="nounderline abstract_t">Gotuzzo E, Seas C, Echevarría J, et al. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 1995; 20:1485.</a></li><li><a class="nounderline abstract_t">Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 1996; 348:296.</a></li><li><a class="nounderline abstract_t">Dutta D, Bhattacharya SK, Bhattacharya MK, et al. Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. J Antimicrob Chemother 1996; 37:575.</a></li><li><a class="nounderline abstract_t">Saha D, Khan WA, Karim MM, et al. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet 2005; 366:1085.</a></li><li><a class="nounderline abstract_t">Saha D, Karim MM, Khan WA, et al. Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 2006; 354:2452.</a></li><li><a class="nounderline abstract_t">Khan WA, Saha D, Ahmed S, et al. Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1. PLoS One 2015; 10:e0134921.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Cholera outbreak --- Haiti, October 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1411.</a></li><li><a class="nounderline abstract_t">Shah MM, Bundi M, Kathiiko C, et al. Antibiotic-Resistant Vibrio cholerae O1 and Its SXT Elements Associated with Two Cholera Epidemics in Kenya in 2007 to 2010 and 2015 to 2016. Microbiol Spectr 2023; 11:e0414022.</a></li><li class="breakAll">Khan WA, Ahmed S, Salam MA, et al. Single-Dose Azithromycin Is Superior to 6-Dose Ciprofloxacin in Adult Cholera: Results of a Double-Blind Randomized Controlled Trial. Abstract 207. Infectious Diseases Society of America, Vancouver, Canada 2010.</li><li><a class="nounderline abstract_t">Khan WA, Saha D, Rahman A, et al. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. Lancet 2002; 360:1722.</a></li><li><a class="nounderline abstract_t">Kaushik JS, Gupta P, Faridi MM, Das S. Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr 2010; 47:309.</a></li><li><a class="nounderline abstract_t">Faruque AS, Alam K, Malek MA, et al. Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. J Health Popul Nutr 2007; 25:241.</a></li><li><a class="nounderline abstract_t">Roy SK, Hossain MJ, Khatun W, et al. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ 2008; 336:266.</a></li><li><a class="nounderline abstract_t">Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967; 36:871.</a></li><li><a class="nounderline abstract_t">Clemens JD, Nair GB, Ahmed T, et al. Cholera. Lancet 2017; 390:1539.</a></li><li><a class="nounderline abstract_t">Mosley WH, Benenson AS, Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ 1968; 38:327.</a></li><li><a class="nounderline abstract_t">Hirschhorn N, Chowdhury AK, Lindenbaum J. Cholera in pregnant women. Lancet 1969; 1:1230.</a></li><li><a class="nounderline abstract_t">Tran NT, Taylor R, Antierens A, Staderini N. Cholera in Pregnancy: A Systematic Review and Meta-Analysis of Fetal, Neonatal, and Maternal Mortality. PLoS One 2015; 10:e0132920.</a></li><li><a class="nounderline abstract_t">Khan AI, Chowdhury F, Leung DT, et al. Cholera in pregnancy: Clinical and immunological aspects. Int J Infect Dis 2015; 39:20.</a></li><li class="breakAll">Global WASH Fast Facts. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases at CDC. https://www.cdc.gov/healthywater/global/wash_statistics.html (Accessed on September 08, 2023).</li><li class="breakAll">World Health Organization. Progress on household drinking-water, sanitation and hygiene 2000-2022: Special focus on gender. https://www.who.int/publications/m/item/progress-on-household-drinking-water--sanitation-and-hygiene-2000-2022---special-focus-on-gender (Accessed on October 16, 2023).</li><li><a class="nounderline abstract_t">DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821.</a></li><li><a class="nounderline abstract_t">Swerdlow DL, Ries AA. Cholera in the Americas. Guidelines for the clinician. JAMA 1992; 267:1495.</a></li><li><a class="nounderline abstract_t">Craun G, Swerdlow D, Tauxe R, et al. Prevention of water-borne cholera in the United States. J Am Waterworks Assoc 1991; 83:40.</a></li><li><a class="nounderline abstract_t">Glass RI, Becker S, Huq MI, et al. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol 1982; 116:959.</a></li><li><a class="nounderline abstract_t">Ali M, Emch M, Park JK, et al. Natural cholera infection-derived immunity in an endemic setting. J Infect Dis 2011; 204:912.</a></li><li><a class="nounderline abstract_t">Kauffman RC, Bhuiyan TR, Nakajima R, et al. Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. mBio 2016; 7.</a></li><li><a class="nounderline abstract_t">Charles RC, Kelly M, Tam JM, et al. Humans Surviving Cholera Develop Antibodies against Vibrio cholerae O-Specific Polysaccharide That Inhibit Pathogen Motility. mBio 2020; 11.</a></li><li><a class="nounderline abstract_t">Levine MM, Nalin DR, Craig JP, et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg 1979; 73:3.</a></li><li><a class="nounderline abstract_t">Iyer AS, Harris JB. Correlates of Protection for Cholera. J Infect Dis 2021; 224:S732.</a></li><li><a class="nounderline abstract_t">Deen J, Holmgren J, Clemens JD. Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges. Lancet Infect Dis 2022; 22:e292.</a></li><li><a class="nounderline abstract_t">Wiens KE, Iyer AS, Bhuiyan TR, et al. Predicting Vibrio cholerae infection and symptomatic disease: a systems serology study. Lancet Microbe 2023; 4:e228.</a></li><li><a class="nounderline abstract_t">Bornside GH. Waldemar Haffkine's cholera vaccines and the Ferran-Haffkine priority dispute. J Hist Med Allied Sci 1982; 37:399.</a></li><li><a class="nounderline abstract_t">Bornside GH. Jaime Ferran and preventive inoculation against cholera. Bull Hist Med 1981; 55:516.</a></li><li><a class="nounderline abstract_t">Mosley WH, McCormack WM, Ahmed A, et al. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ 1969; 40:187.</a></li><li><a class="nounderline abstract_t">Bi Q, Ferreras E, Pezzoli L, et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17:1080.</a></li><li><a class="nounderline abstract_t">Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1694.</a></li><li><a class="nounderline abstract_t">Bhattacharya SK, Sur D, Ali M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013; 13:1050.</a></li><li><a class="nounderline abstract_t">Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 2015; 386:1362.</a></li><li><a class="nounderline abstract_t">Qadri F, Wierzba TF, Ali M, et al. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med 2016; 374:1723.</a></li><li><a class="nounderline abstract_t">Qadri F, Ali M, Lynch J, et al. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. Lancet Infect Dis 2018; 18:666.</a></li><li><a class="nounderline abstract_t">Ali M, Sur D, You YA, et al. Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India. Clin Infect Dis 2013; 56:1123.</a></li><li><a class="nounderline abstract_t">Luquero FJ, Grout L, Ciglenecki I, et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 2014; 370:2111.</a></li><li><a class="nounderline abstract_t">Franke MF, Ternier R, Jerome JG, et al. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study. Lancet Glob Health 2018; 6:e1028.</a></li><li><a class="nounderline abstract_t">van Loon FP, Clemens JD, Chakraborty J, et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 1996; 14:162.</a></li><li><a class="nounderline abstract_t">Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270.</a></li><li><a class="nounderline abstract_t">Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 2005; 366:44.</a></li><li><a class="nounderline abstract_t">Lucas ME, Deen JL, von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352:757.</a></li><li><a class="nounderline abstract_t">Khatib AM, Ali M, von Seidlein L, et al. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis 2012; 12:837.</a></li><li><a class="nounderline abstract_t">Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis 2016; 62:1329.</a></li><li><a class="nounderline abstract_t">Collins JP, Ryan ET, Wong KK, et al. Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022. MMWR Recomm Rep 2022; 71:1.</a></li><li><a class="nounderline abstract_t">McCarty JM, Cassie D, Bedell L, et al. Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States. Am J Trop Med Hyg 2021; 104:1758.</a></li><li><a class="nounderline abstract_t">McCarty JM, Gierman EC, Bedell L, et al. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years. Am J Trop Med Hyg 2020; 102:48.</a></li><li><a class="nounderline abstract_t">McCarty JM, Cassie D, Bedell L, et al. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2-5 Years in the United States. Am J Trop Med Hyg 2020; 104:861.</a></li><li><a class="nounderline abstract_t">Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399.</a></li><li><a class="nounderline abstract_t">Harris JB. Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine. Clin Infect Dis 2016; 62:1336.</a></li><li><a class="nounderline abstract_t">Sharma T, Joshi N, Kumar Mandyal A, et al. Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine. Vaccine 2020; 38:7998.</a></li><li><a class="nounderline abstract_t">Jeon S, Kelly M, Yun J, et al. Scalable production and immunogenicity of a cholera conjugate vaccine. Vaccine 2021; 39:6936.</a></li><li><a class="nounderline abstract_t">Hubbard TP, Billings G, Dörr T, et al. A live vaccine rapidly protects against cholera in an infant rabbit model. Sci Transl Med 2018; 10.</a></li><li class="breakAll">Ending Cholera - A Global Roadmap to 2030. World Health Organization. https://www.gtfcc.org/wp-content/uploads/2019/10/gtfcc-ending-cholera-a-global-roadmap-to-2030.pdf (Accessed on June 12, 2023).</li><li><a class="nounderline abstract_t">Burki T. Addressing the shortage of cholera vaccines. Lancet Infect Dis 2022; 22:1674.</a></li><li><a class="nounderline abstract_t">Qadri F, Azad AK, Flora MS, et al. Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh. Lancet 2018; 391:1877.</a></li><li><a class="nounderline abstract_t">Khan AI, Islam MT, Siddique SA, et al. Post-vaccination campaign coverage evaluation of oral cholera vaccine, oral polio vaccine and measles-rubella vaccine among Forcibly Displaced Myanmar Nationals in Bangladesh. Hum Vaccin Immunother 2019; 15:2882.</a></li><li><a class="nounderline abstract_t">Ivers LC. Eliminating Cholera Transmission in Haiti. N Engl J Med 2017; 376:101.</a></li><li><a class="nounderline abstract_t">Rubin DHF, Zingl FG, Leitner DR, et al. Reemergence of Cholera in Haiti. N Engl J Med 2022; 387:2387.</a></li><li><a class="nounderline abstract_t">Ferreras E, Chizema-Kawesha E, Blake A, et al. Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia. N Engl J Med 2018; 378:577.</a></li><li><a class="nounderline abstract_t">Pezzoli L, Oral Cholera Vaccine Working Group of the Global Task Force on Cholera Control. Global oral cholera vaccine use, 2013-2018. Vaccine 2020; 38 Suppl 1:A132.</a></li><li class="breakAll">Presented at the 9th Meeting of the GTFCC WGoOCV, October 11-12, 2022, Les Pensières, Center For Global Health, Veyrier-Du-Lac (France). https://www.gtfcc.org/wp-content/uploads/2022/11/9th-meeting-of-gtfcc-wg-ocv-2022-overview-malika-bouhenia.pdf. (Accessed on January 30, 2023).</li><li class="breakAll">Devi S. Cholera vaccines rationed amid global shortage. The Lancet 2022; 400:1502. https://doi.org/10.1016/S0140-6736(22)02116-X (Accessed on June 12, 2023).</li></ol></div><div id="topicVersionRevision">Topic 141337 Version 2.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35397865" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35397865" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5442912" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Water and electrolyte losses due to cholera in infants and small children: a recovery balance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6262471" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Stool electrolyte content and purging rates in diarrhea caused by rotavirus, enterotoxigenic E. coli, and V. cholerae in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451782" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882963" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Amylase-resistant starch plus oral rehydration solution for cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21146206" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Five complementary interventions to slow cholera: Haiti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical studies in Asiatic cholera. IV. Antibiotic therapy in cholera</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4968807" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4873660" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Controlled comparison of tetracycline and furazolidone in cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24944120" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antimicrobial drugs for treating cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25114012" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bacterial shedding in household contacts of cholera patients in Dhaka, Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142691" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antibiotics for both moderate and severe cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196962" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomised double blind trial of single dose doxycycline for treating cholera in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7646639" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2569589" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Simultaneous outbreaks of contrasting drug resistant classic and El Tor Vibrio cholerae O1 in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21252269" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibiotic resistance mechanisms of Vibrio cholerae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952318" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7548496" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8709688" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182114" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182896" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760445" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Single-dose azithromycin for the treatment of cholera in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26271050" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of Ciprofloxacin for Treatment of Cholera Associated with Diminished Susceptibility to Ciprofloxacin to Vibrio cholerae O1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048563" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cholera outbreak --- Haiti, October 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37125926" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antibiotic-Resistant Vibrio cholerae O1 and Its SXT Elements Associated with Two Cholera Epidemics in Kenya in 2007 to 2010 and 2015 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37125926" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antibiotic-Resistant Vibrio cholerae O1 and Its SXT Elements Associated with Two Cholera Epidemics in Kenya in 2007 to 2010 and 2015 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480424" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578229" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17985827" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Emergence of multidrug-resistant strain of Vibrio cholerae O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184631" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4865453" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antibiotic therapy of cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28302312" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5302327" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4182412" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cholera in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26177291" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cholera in Pregnancy: A Systematic Review and Meta-Analysis of Fetal, Neonatal, and Maternal Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283553" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cholera in pregnancy: Clinical and immunological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283553" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cholera in pregnancy: Clinical and immunological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26283553" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cholera in pregnancy: Clinical and immunological aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8502272" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevention and treatment of traveler's diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1371570" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cholera in the Americas. Guidelines for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevention of water-borne cholera in the United States</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7148820" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Endemic cholera in rural Bangladesh, 1966-1980.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849288" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Natural cholera infection-derived immunity in an endemic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999163" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33203761" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Humans Surviving Cholera Develop Antibodies against Vibrio cholerae O-Specific Polysaccharide That Inhibit Pathogen Motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/442179" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34668561" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Correlates of Protection for Cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35533702" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36907197" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predicting Vibrio cholerae infection and symptomatic disease: a systems serology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6759570" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Waldemar Haffkine's cholera vaccines and the Ferran-Haffkine priority dispute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039738" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Jaime Ferran and preventive inoculation against cholera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5306539" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population--the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729167" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19819004" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140390" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26164097" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27144848" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29550406" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362293" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24869721" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Use of Vibrio cholerae vaccine in an outbreak in Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30103980" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8852414" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1967730" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15993232" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728808" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effectiveness of mass oral cholera vaccination in Beira, Mozambique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22954655" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001804" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36173766" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33819178" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12-17 Years in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31769402" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33319739" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2-5 Years in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738097" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001802" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Editorial Commentary: Resurrecting a Live Oral Cholera Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33139137" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Development of Hillchol®, a low-cost inactivated single strain Hikojima oral cholera vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34716040" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Scalable production and immunogenicity of a cholera conjugate vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29899024" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A live vaccine rapidly protects against cholera in an infant rabbit model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29899024" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A live vaccine rapidly protects against cholera in an infant rabbit model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36435186" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Addressing the shortage of cholera vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29781432" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31441679" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Post-vaccination campaign coverage evaluation of oral cholera vaccine, oral polio vaccine and measles-rubella vaccine among Forcibly Displaced Myanmar Nationals in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959699" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Eliminating Cholera Transmission in Haiti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36449726" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Reemergence of Cholera in Haiti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414267" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31519444" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Global oral cholera vaccine use, 2013-2018.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
